Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07664891

Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma

The present project aims to elucidate the metabolic interactions within the tumor microenvironment of pancreatic adenocarcinoma, both in the primary tumor and in hepatic and pulmonary metastatic sites, as well as in circulating blood biomarkers.

Deciphering these complex interactions aims to identify exploitable vulnerabilities for predicting treatment efficacy or for guiding therapeutic strategies.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pancreatic Adenocarcinoma Metastatic

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Institut Paoli-Calmettes

Marseille, 13009, France

Location status: Recruiting

Location contact

Jihane PAKRADOUNI

CONTACT

[email protected]

+334 91223778

About this study

Pancreatic adenocarcinoma (PDAC) remains one of the deadliest cancers, with survival rarely exceeding a few months and limited progress despite improved chemotherapy. Its poor prognosis is driven by late diagnosis, therapeutic resistance, and low responsiveness to targeted therapies and immunotherapy.

PDAC is characterized by a dense, immunosuppressive stroma and severe metabolic stress due to poor vascularization. Tumor progression relies heavily on stromal cells-such as cancer-associated fibroblasts and macrophages-as well as metabolic adaptations of cancer cells.

This project focuses on two key PDAC features to identify new biomarkers and therapeutic targets:

  • Stromal cell prevalence
  • Metabolic reprogramming

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18 years
  • Signed written informed consent specific to the PROMETAP study
  • Affiliation with a social security system
  • Treatment and follow-up performed at the Institut Paoli-Calmettes
  • Metastatic PDAC requiring biopsy as part of routine care (group1 and 2)
  • Prior treatment:
  • No previous chemotherapy for the "initial" group
  • No prior chemotherapy in the metastatic setting for the "Metastatic Relapse" group
  • Eligible for chemotherapy (ECOG < 2)

Non-Inclusion Criteria:

  • Contraindication to biopsy of the pancreatic tumor or a hepatic or pulmonary metastasis (group 1 and 2)
  • Absence of a metastasis accessible to biopsy (group1 and 2)
  • Concurrent treatment for another active cancer
  • Pregnant or breastfeeding women
  • Patients in emergency situations
  • Adult individuals under legal protection (guardianship, trusteeship, judicial protection) or unable to provide informed consent

Treatment and study plan

Biopsy collection

Other

Tumor cells isolation

Blood collection

Other

Isolation of blood monocytes

Primary outcomes

  1. Evaluation and comparison of biological parameters reflecting metabolic alterations within the tumor microenvironment of pancreatic adenocarcinoma

    Time frame: From sample collection to completion of analyses, estimated at 3 years

    • Assessment of stromal dependency mechanisms;
    • Characterization and comparison of the metabolic profiles of primary pancreatic tumors and associated liver and lung metastases.

    These analyses aim to identify potential therapeutic targets and to explore diagnostic, prognostic, and predictive biomarkers of treatment response.

Secondary outcomes

  1. Exploratory characterization of metabolic pathways, tumor microenvironment features, and associated biomarkers in pancreatic adenocarcinoma.

    Time frame: From sample collection to completion of analyses, estimated at 3 years

    • Identification of prognostic markers of therapeutic response originating from the tumor microenvironment.
    • Identification of mechanisms of resistance to anti-tumor treatments linked to the microenvironment.
    • Identification of new therapeutic strategies capable of specifically targeting the tumor microenvironment.

Study contacts

Contact information is provided by the study sponsor or research team.

Jihane PAKRADOUNI

CONTACT

[email protected]

+334 91223778

Sponsors and collaborators

Lead sponsor

Institut Paoli-Calmettes

Other

Registry information

Official study title

Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma: Identification of New Therapeutic Targets

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Jun 24, 2026
Registry last updated
Jun 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.